2Souli M,Wennersten CB,Eliopoulous GM.In vitro activity of BAY 128039, a new fluoroquinolone, against species representative of respiratory tract pathogens[].International Journal of Antimicrobial Agents.1998
3Bradford WZ,Daley CL.Multiple drug-resistant tuberculosis[].Infectious Diseases in Clinical Practice.1998
4Aldridge KE,Ashcraft DS.Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes[].Antimicrobial Agents and Chemotherapy.1997
5Fass RJ.In vitro activity of Bay 12-8039, a new 8-methoxyquinolone[].Antimicrobial Agents and Chemotherapy.1997
6Visalli MA,Jacobs MR,Appelbaum PC.Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams[].Antimicrobial Agents and Chemotherapy.1997
7Stass HH,Kubitza D.Study to evaluate the interaction between moxifloxacin ( M ) and iron supplements ( FE )[].Antiinfect Drug Chemother.1998
8Klugman KP,Capper T.Concentration-dependent killing of antibioticresistant pneumococci by the methoxyquinolone moxifloxacin[].Journal of Antimicrobial Chemotherapy.1997
9Woodcock JM,Andrews JM,Boswell JF,et al.In vitro activity of BAY 12-8039, a new fluoroquinolone[].Antimicrobial Agents and Chemotherapy.1997
10Wise R.A review of the clinical pharmacology of moxifloxacin , a new 8methoxyquinolone, and its potential relation to therapeutic efficacy[].Clin Drug Inves.1999
